Glecaprevir-Pibrentasvir in GT 1-6 with Renal Disease
EXPEDITION-4

Source: Gane E, et al. N Engl J Med. 2017;377:1448-55.

Glecaprevir-Pibrentasvir in Genotype 1-6 with Renal Disease
EXPEDITION-4: Study Features

- **Design**: Open-label, single-arm, phase 3 trial to evaluate the safety and efficacy of the fixed-dose combination of glecaprevir-pibrentasvir for 12 weeks in treatment-naïve and treatment-experienced patients with GT 1, 2, 3, 4, 5, or 6 chronic HCV infection with advanced renal insufficiency
- **Setting:** US, Canada, Europe, Australia and New Zealand
- **Key Eligibility Criteria**
  - Age ≥18 years
  - Chronic HCV GT 1, 2, 3, 4, 5, or 6
  - Estimated eGFR <30 mL/min/1.73 m^2 (Stage 4 or 5 CKD)
  - HCV RNA ≥1,000 IU/mL at screening
  - Naïve or treated with peginterferon +/- ribavirin (PR) or PR +/- sofosbuvir
  - Without cirrhosis or with compensated cirrhosis
  - HIV or chronic HBV coinfection excluded
- **Primary End Point**: SVR12

Source: Gane E, et al. N Engl J Med. 2017;377:1448-55.

Glecaprevir-Pibrentasvir in Genotype 1-6 with Renal Disease
EXPEDITION-4: Treatment Regimen



Abbreviations: CKD = chronic kidney disease
Drug Dosing: Glecaprevir-pibrentasvir (100/40 mg) fixed-dose combination, three pills daily

Source: Gane E, et al. N Engl J Med. 2017;377:1448-55.

Glecaprevir-Pibrentasvir in Genotype 1-6 with Renal Disease
EXPEDITION-4: Baseline Characteristics

Baseline Characteristic	Glecaprevir-Pibrentasvir (n = 104)
Mean age (range), years	57 (28-83)
Male sex, n (%)	79 (76)
Race, n (%)	
White	64 (62)
Black	25 (24)
Asian	9 (9)
Other	6 (6)
Median body-mass index (range)	26 (18-45)
Compensated cirrhosis, n (%)	20 (19)

Source: Gane E, et al. N Engl J Med. 2017;377:1448-55.

Glecaprevir-Pibrentasvir in Genotype 1-6 with Renal Disease
EXPEDITION-4: Baseline Characteristics

Baseline Characteristic	Glecaprevir-Pibrentasvir (n = 104)
Median HCV RNA level, log_{10} IU/mL (range)	5.9 (3.4-7.5)
HCV Genotypes, n (%)	
1a	23 (22)
1b	29 (28)
1 (other)	2 (2)
2	17 (16)
3	11 (11)
4	20 (19)
5	1 (1)
6	1 (1)
HCV Treatment History, n (%)	
Treatment-Naïve	60 (58)
Interferon (or Peginterferon) ± Ribavirin	42 (40)
Sofosbuvir and Ribavirin ± Peginterferon	2 (2)

Source: Gane E, et al. N Engl J Med. 2017;377:1448-55.

Glecaprevir-Pibrentasvir in Genotype 1-6 with Renal Disease
EXPEDITION-4: Baseline Characteristics (Renal)

Baseline Characteristics (Renal)	Glecaprevir-Pibrentasvir (n = 104)
eGFR in patients not undergoing hemodialysis, mL/min/1.73 m^2	20.6 ± 8.0
CKD stage, n (%)	
Stage 4	14 (13)
Stage 5	90 (87)
Hemodialysis, n (%)	85 (82)

Source: Gane E, et al. N Engl J Med. 2017;377:1448-55.

Glecaprevir-Pibrentasvir in Genotype 1-6 with Renal Disease EXPEDITION-4: Results

Sustained Virologic Response Rates (SVR)



Source: Gane E, et al. N Engl J Med. 2017;377:1448-55.

Glecaprevir-Pibrentasvir in Genotype 1-6 with Renal Disease EXPEDITION-4: Results

Sustained Virologic Response Rates (SVR)



Source: Gane E, et al. N Engl J Med. 2017;377:1448-55.

Glecaprevir-Pibrentasvir in Genotype 1-6 with Renal Disease
EXPEDITION-4: Adverse Events

Adverse Event (AE), n (%)	Glecaprevir-Pibrentasvir (n = 104)
Serious AE	25 (24)
AE leading to treatment discontinuation	4 (4)*
Death	1 (1)[#]
AEs occurring in ≥10% of patients	
Pruritus	21 (20)
Fatigue	15 (14)
Nausea	12 (12)
Alanine aminotransferase >3x ULN, grade ≥2	0
Total bilirubin >3x ULN, grade ≥3	1 (1)
Hemoglobin <8 g/dL, grade ≥3	5 (5)

*AEs not considered related to study drug
[#]One death related to cerebral hemorrhage, post-treatment week 2, deemed not related to study drug.

Source: Gane E, et al. N Engl J Med. 2017;377:1448-55.

Glecaprevir-Pibrentasvir in Genotype 1-6 with Renal Disease
EXPEDITION-4: Conclusions

Conclusion: “Treatment with glecaprevir and pibrentasvir for 12 weeks resulted in a high rate of sustained virologic response in patients with stage 4 or 5 chronic kidney disease and HCV infection.”

Source: Gane E, et al. N Engl J Med. 2017;377:1448-55.

Acknowledgments

Hepatitis C Online is funded by a cooperative agreement from the Centers for Disease Control and Prevention (CDC-RFA- PS21-2105). This project is led by the University of Washington Infectious Diseases Education and Assessment (IDEA) Program.

HEPATITIS B ONLINE

HEPATITIS C ONLINE

IDEA INFECTIOUS DISEASES EDUCATION & ASSESSMENT